Among genotype 1 patients , eRVR rates ( asunaprevir vs. placebo ) were 67 % ( 80 % CI 62 , 72 ) vs. 6 % ( 80 % CI 2 , 10 ) ; corresponding SVR24 rates were 64 % ( 80 % CI 59 , 68 ) vs. 44 % ( 80 % CI 36 , 53 ) .